Loading clinical trials...
Loading clinical trials...
An Open-Label, Randomised, Single Dose, Two-Way Crossover Pilot Study to Determine the Relative Bioavailability of a Fixed Dose Combination Tablet Formulation of GSK587323 (16mg Candesartan Cilexetil/12.5mg Hydrochlorothiazide) Relative to Respective Reference Dosage Atacand D in Healthy Adult Human Subjects Under Fasting Conditions
Conditions
Interventions
GSK587323
FDC of candesartan cilexetil 16 mg and HCTZ 12.5mg
Locations
1
India
GSK Investigational Site
Hyderabad, India
Start Date
April 17, 2014
Primary Completion Date
May 23, 2014
Completion Date
May 23, 2014
Last Updated
May 15, 2017
NCT02417740
NCT07480265
NCT07073820
NCT06876233
NCT06062394
NCT06899815
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions